Patents by Inventor Chul Woong Chung

Chul Woong Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230310640
    Abstract: The present invention relates to a pyrrolobenzodiazepine derivative compound, a conjugate of the same with a ligand, and the use of the same. The pyrrolobenzodiazepine derivative compound is more stable in plasma, is stable even in circulation, and exhibits excellent efficacy. In particular, the conjugate of the pyrrolobenzodiazepine derivative compound with a ligand has a great advantage in that it is possible to target and specifically treat proliferative disease such as cancer, maximize drug efficacy, and minimize the expression of side effects since the conjugate more stably reaches the target cell and effectively exerts drug efficacy while toxicity is greatly reduced as a linker technology that allows drugs to be easily released within cancer cells and maximize drug efficacy is incorporated.
    Type: Application
    Filed: December 30, 2020
    Publication date: October 5, 2023
    Inventors: Ho Young SONG, Yun-Hee PARK, Kun Jung LEE, Ji Hye OH, Sung Min KIM, Kyung Eun PARK, Yong Gyu PARK, Hyun Min RYU, Na Ra HAN, Chul Woong CHUNG, Jei Wook CHAE, Yong Zu KIM
  • Publication number: 20230270868
    Abstract: The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.
    Type: Application
    Filed: February 24, 2023
    Publication date: August 31, 2023
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun-Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun Joung Lee, Ju Young Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Patent number: 11654197
    Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: May 23, 2023
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun Joung Lee, Ju Young Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Publication number: 20230123569
    Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.
    Type: Application
    Filed: December 1, 2022
    Publication date: April 20, 2023
    Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
  • Patent number: 11548883
    Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 10, 2023
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
  • Patent number: 11413353
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 16, 2022
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20220218830
    Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.
    Type: Application
    Filed: March 29, 2018
    Publication date: July 14, 2022
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun J. Lee, Ju Y. Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Publication number: 20220218840
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Application
    Filed: November 12, 2021
    Publication date: July 14, 2022
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Patent number: 11173214
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 16, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Patent number: 11167040
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 9, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Patent number: 10980890
    Abstract: Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: April 20, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
  • Patent number: 10961242
    Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: March 30, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
  • Publication number: 20200407350
    Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.
    Type: Application
    Filed: May 15, 2018
    Publication date: December 31, 2020
    Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
  • Publication number: 20200297865
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Application
    Filed: November 23, 2016
    Publication date: September 24, 2020
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20200172529
    Abstract: Provided are a pyrimidinyl amino compound having protein kinase inhibitor activity, and a pharmaceutical composition containing said compound; also provided are a use and application of said compound. What is provided is selected from a group consisting of the compound represented by formula (I), a stereoisomer thereof, a tautomer thereof, a pharmacologically acceptable salt thereof, a solvate thereof, and a prodrug thereof. The described compound has good inhibitory activity against the JAK family of kinases and the SYK family of kinases, and therefore may serve as a JAK inhibitor and SYK inhibitor, and is effective in use for the prevention or treatment of diseases related to the JAK and SYK families of kinases.
    Type: Application
    Filed: August 17, 2018
    Publication date: June 4, 2020
    Applicant: Beijing Hanmi Pharm. Co., Ltd.
    Inventors: Tao ZHAO, Dong WEI, Min LI, Maeng Sup KIM, Chul Woong CHUNG
  • Publication number: 20200172542
    Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 4, 2020
    Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
  • Publication number: 20200069816
    Abstract: Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
    Type: Application
    Filed: August 20, 2019
    Publication date: March 5, 2020
    Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
  • Publication number: 20190381185
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Application
    Filed: November 23, 2016
    Publication date: December 19, 2019
    Applicant: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Patent number: 10383949
    Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: August 20, 2019
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
  • Publication number: 20190151465
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Application
    Filed: November 23, 2016
    Publication date: May 23, 2019
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee